Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05514873 · ClinicalTrials.gov registry record · Phase 3
An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
A Phase 3 study, sponsored by UCB Biopharma SRL.
- Completed
- Registry status
- Phase 3
- Development phase
- 26
- Enrollment target
NCT05514873 is a Phase 3 study that has completed, run by UCB Biopharma SRL. The registered enrollment target is 26 participants.
The verdict
NCT05514873, a Phase 3 study, has completed, sponsored by UCB Biopharma SRL.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and tolerability of switching from intravenous (IV) complement component 5 (C5) inhibitors to subcutaneous (SC) Zilucoplan in study participants with generalized myasthenia gravis (gMG)
Interventions
- DRUG zilucoplan (RA101495)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2022-10-31 |
| Est. Completion | 2024-10-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05514873
The ClinicalTrials.gov registry entry for NCT05514873 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which zilucoplan (RA101495) is the first listed.
NCT05514873 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05514873 about?
NCT05514873 is a clinical study titled "An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors". The purpose of the study is to evaluate the safety and tolerability of switching from intravenous (IV) complement component 5 (C5) inhibitors to subcutaneous (SC) Zilucoplan in study participants with generalized myasthenia gravis (gMG)
What is the current status of trial NCT05514873?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 26 participants. The study started on 2022-10-31. Estimated completion is 2024-10-23.
What interventions are being tested in trial NCT05514873?
The interventions under investigation include: zilucoplan (RA101495) (DRUG).
Who is sponsoring clinical trial NCT05514873?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.